We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Memantine hydrochloride Alzheimer's disease Film-coated tablets 5, 10, 15 and 20 mg
Memantine hydrochloride Alzheimer's disease Oral solution 10 mg/ml
Methocarbamol Muscle spasms, pain Film-coated tablets 750 mg
Methocarbamol Muscle spasms, pain Film-coated tablets 1.5 mg
Montelukast Asthma, allergy Chewable tablets 4 and 5 mg
Montelukast Asthma, allergy Film-coated tablets 10 mg
Nabilone * Antiemetic Film-coated tablets 1 mg
Noxiall® Useful to contrast chronic and neuropathic pain Jan 2017
Olanzapine Psychosis, schizophrenia Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg
Olanzapine Psychosis, schizophrenia Orodispersable tablets 5, 10, 15 and 20 mg
Ondansetron Nausea & vomiting Film-coated tablets 4 and 8 mg
Ondansetron Nausea & vomiting Orodispersable tablets 4 and 8 mg
Otilonium bromide Irritable bowel syndrome Film-coated tablets 40 mg
Paracetamol / Tramadol Analgesic Effervescent tablets 325/37.5 mg
Partnena® Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states Jan 2014
Pramipexol Parkinson's Tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Prasugrel Base Prophylaxis and therapy of thrombosis Film-coated tablets 5 and 10 mg
Pregabaline * Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.